15 completed, 3 unknown, 3 withdrawn, 1 terminated. 9 Phase 2, 9 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Withdrawn 2, Unknown 1 |
| Phase 3 | 9 | Completed 5, Unknown 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
Follow peginterferon lambda-1a: new trials by email Literature Review of peginterferon lambda-1a trials Research Report on peginterferon lambda-1a
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis Peginterferon Lambda - Chronic Hepatitis Delta | Phase 2 | Withdrawn | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2024-05-22 | 2024-05-23 | |
| Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV Peginterferon Lambda-1a - Hepatitis Delta Virus | Phase 3 | Unknown | Eiger BioPharmaceuticals | 150 | 2021-12-21 | 2023-08-25 |
| TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19 Peginterferon Lambda-1A, Placebo - Sars-CoV2, Covid19 | Phase 3 | Unknown | University Health Network, Toronto | 763 | 2021-08-27 | 2022-04-05 |
| Interferon Lambda Therapy for COVID-19 Peginterferon Lambda-1A - SARS-CoV-2 | Phase 2 | Withdrawn | Icahn School of Medicine at Mount Sinai | 2020-09-01 | 2021-02-26 | |
| Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19 Peginterferon Lambda-1A, placebo - Sars-CoV2, Covid-19 | Phase 2 | Completed | University Health Network, Toronto | 157 | 2020-05-13 | 2023-12-13 |
| Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19 Peginterferon Lambda-1a, Placebo - COVID-19 | Phase 2 | Completed | Stanford University | 120 | 2020-04-25 | 2021-11-30 |
| A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection Peginterferon Lambda-1A - Hepatitis D, Chronic | Phase 2 | Completed | EIT Pharma, Inc. | 33 | 2016-10-19 | 2026-09-08 |
| The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients Peginterferon lambda - Hepatitis C | Phase 1 | Completed | Nanogen Pharmaceutical Biotechnology Joint Stock Company | 60 | 2013-12-01 | 2016-12-15 |
| Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV Pegylated Interferon Lambda-1a, Daclatasvir (DCV), Ribasphere (RBV) - Chronic Hepatitis C Infection | Phase 3 | Terminated | Bristol-Myers Squibb | 453 | 2013-07-11 | 2023-06-13 |
| Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia Pegylated-Interferon-lambda, Ribavirin, Daclatasvir - Hepatitis C Virus | Phase 3 | Completed | Bristol-Myers Squibb | 71 | 2013-03-31 | 2020-08-11 |
| Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C Peginterferon Lambda-1a, Ribavirin, Peginterferon alfa-2a - Hepatitis C Virus (HCV) | Phase 3 | Completed | Bristol-Myers Squibb | 40 | 2013-03-01 | 2015-01-28 |
| Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin Pegylated Interferon Lambda, Ribasphere, Daclatasvir - Hepatitis C | Phase 2 | Completed | Bristol-Myers Squibb | 165 | 2013-03-01 | 2015-10-09 |
| Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin - Hepatitis C | Phase 3 | Completed | Bristol-Myers Squibb | 444 | 2013-01-01 | 2015-10-09 |
| Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction BMS-914143 (Peginterferon Lambda-1a) - Chronic Hepatitis B Virus Infection, Chronic Hepatitis C Virus Infection | Phase 1 | Completed | Bristol-Myers Squibb | 43 | 2012-09-01 | 2013-06-05 |
| Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 Pegylated interferon lambda (pegIFNλ), Pegylated interferon alfa-2a (pegIFNα-2a), Ribavirin - Hepatitis C Virus (HCV) | Phase 3 | Completed | Bristol-Myers Squibb | 880 | 2012-07-01 | 2015-10-09 |
| Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin - Hepatitis C Virus | Phase 3 | Completed | Bristol-Myers Squibb | 881 | 2012-06-14 | 2019-07-31 |
| Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial Peginterferon Lambda-1a (BMS-914143) - Hepatitis C | Completed | Bristol-Myers Squibb | 218 | 2012-03-01 | 2015-03-26 | |
| Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Pegylated Interferon Lambda, Pegylated Interferon Alfa-2a, Ribavirin - Hepatitis C Virus (HCV) | Phase 3 | Withdrawn | Bristol-Myers Squibb | 2012-03-01 | 2012-02-03 | |
| Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin Pegylated Interferon Lambda (pegIFNλ), BMS-790052 (NS5A Inhibitor), Ribavirin (RBV) - Hepatitis C | Phase 2 | Completed | Bristol-Myers Squibb | 165 | 2011-03-01 | 2015-10-09 |
| Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen pegIFN, pegIFNα-2a, PegIFN lambda - Hepatitis B Virus | Phase 2 | Completed | Bristol-Myers Squibb | 197 | 2010-11-01 | 2015-10-09 |
Showing 20 of 22. Sign in to see all of them.
Hepatitis C (12) · COVID-19 (3) · Hepatitis C, Chronic (2) · Hepatitis D (2) · Hepatitis D, Chronic (2) · Infections (2) · Virus Diseases (2) · Coronavirus Infections (1) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Liver Diseases (1)
Bristol-Myers Squibb (12) · University Health Network, Toronto (2) · ZymoGenetics (2) · EIT Pharma, Inc. (1) · Eiger BioPharmaceuticals (1) · Icahn School of Medicine at Mount Sinai (1) · Nanogen Pharmaceutical Biotechnology Joint Stock Company (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Stanford University (1)
United States (16) · France (10) · Italy (10) · Canada (9) · Spain (9) · Germany (8) · Australia (6) · Poland (6) · Russia (6) · South Korea (6) · Belgium (5) · Netherlands (5) · Romania (5) · United Kingdom (5) · Argentina (4)
Jordan Feld, MD (2) · Christopher Koh, M.D. (1) · David Apelian, MD, PhD, MBA (1) · Diana F Hausman, MD (1) · Dr.Chinh Trong Nguyen, PhD (1) · Jan Hillson, MD (1) · Thomas Marron, MD (1) · Upinder Singh (1)
PMID 32788708, PMID 23743475, PMID 25042797, PMID 25043197, PMID 26739688, PMID 27327078, PMID 28282271, PMID 28611778, PMID 32555385, PMID 33556319, PMID 33624010, PMID 33785743, PMID 35588734, PMID 37147857, PMID 39663120
2009 (1)